A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.

Llombart-Cussac, Antonio

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. [electronic resource] - Breast (Edinburgh, Scotland) Oct 2014 - 656-62 p. digital

Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1532-3080

10.1016/j.breast.2014.06.017 doi


Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized--administration & dosage
Antineoplastic Agents--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bevacizumab
Breast Neoplasms--drug therapy
Decision Support Techniques
Drug Administration Schedule
Female
Humans
Middle Aged
Prognosis
Receptor, ErbB-2--metabolism
Risk Assessment
Risk Factors
Survival Rate
Taxoids--administration & dosage